Multiple Sclerosis Fatigue (Investigational Adjunct)
Investigational adjunct for MS-related fatigue; no controlled trials; disease-modifying therapy and modafinil/amantadine remain primary.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for multiple sclerosis fatigue. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). No controlled trials. Evidence-based first-line management of MS fatigue is optimization of disease-modifying therapy, treatment of comorbid sleep disorders, depression, and thyroid disease, structured aerobic exercise, and (with mixed but real evidence) amantadine, modafinil, or methylphenidate. Cognitive behavioral therapy specifically for MS fatigue also has RCT support.
- Riesgos principales
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Worsening of MS-related dysautonomia (orthostatic symptoms) after a session that draws blood volume
- Uhthoff phenomenon (heat-induced symptom worsening) if the session room is warm
- Quién no debería considerar esto
- Patients in an active MS relapse (focus must be on the relapse, not adjunctive therapy)
- Patients who have not had MS-specific fatigue evaluated for treatable mimics: anemia, hypothyroidism, depression, sleep apnea
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
- Qué preguntar a su clínico
- Has my fatigue been worked up for treatable causes — anemia, low thyroid, sleep apnea, depression?
- Am I on optimal disease-modifying therapy for my MS subtype?
- Have I tried amantadine, modafinil, or methylphenidate?
- What CBT or graded exercise programs for MS fatigue are available?
- What is the published evidence base for leeches in MS fatigue specifically?
- Could blood loss from sessions worsen my fatigue rather than help it?
- Cuándo buscar atención urgente
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- New or worsening neurologic symptoms — vision change, weakness, numbness, balance loss, bladder problems (possible MS relapse)
- Severe orthostatic dizziness or fainting on standing
Qué NO significa esto
- It does not mean leech therapy is FDA-cleared for MS fatigue — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace MS disease-modifying therapy, which targets the underlying disease.
- It does not address common reversible causes of fatigue such as anemia, thyroid disease, depression, or sleep apnea.
- It does not have controlled-trial evidence in MS.
- It does not modify MS disease activity or progression in any way.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- neurological
- ICD-10
- G35, R53.83
- Safety tier
- high
Evidence Summary
MS fatigue is among the most disabling symptoms in multiple sclerosis. Management per AAN guidance includes addressing depression and sleep disorders, exercise therapy, and pharmacotherapy (amantadine, modafinil, methylphenidate - all off-label, with modest effect sizes). No controlled clinical trial of leech therapy for MS-related fatigue has been published; use is investigational only. Although an antiinflammatory rationale is sometimes proposed given the autoinflammatory nature of MS, there is no clinical evidence to support it. Important: MS patients on natalizumab or other immunosuppressants face increased infection risk, complicating Aeromonas prophylaxis decisions.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Michalsen A et al. (2008)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active MS relapse (treat with corticosteroids first)
- Severe immunosuppression from DMT (natalizumab, alemtuzumab)
- Active urinary tract infection (common in MS)
- Decubitus ulcers or skin breakdown over treatment sites
Related Conditions
Cervical Radiculopathy
Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.
Lumbar Radiculopathy (Sciatica)
Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.
Migraine
Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.
Tension-Type Headache
Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.